Phase I Research at Providence Cancer Center
December 23, 2016
Patients with a variety of cancer types are eligible to receive new and promising treatments when they participate in Phase I research studies at Providence Cancer Center.
Our Phase I clinical research team of physicians, nurses, data coordinators and research assistants meets weekly to discuss all ongoing Phase I trials and to coordinate patient care. As one research nurse summed up: “Everyone on our team is dedicated to providing individualized care to our patients, with the same goal in mind: #FINISHCANCER. That isn’t just a hope or a hashtag; it’s our daily aspiration.”
More than 40 Phase I studies are currently open at Providence Cancer Center, including these two immunotherapy studies open to patients with several types of cancer:
Title: A Phase 1/2, Open-Label, Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of CD122-Biased Cytokine (NKTR-214) and Anti-PD-1 Antibody (Nivolumab) in Patients With Select Locally Advanced or Metastatic Solid Tumor Malignancies
Description: This study is to determine first, the recommended Phase 2 dose of NKTR-214 when administered in combination with nivolumab, and then, the clinical benefit, safety, and tolerability of combining NKTR-214 with nivolumab in select patients with melanoma, renal cell carcinoma or non-small cell lung cancer. Both drugs target the immune system and may act synergistically to promote anti-cancer effects.
Title: A Phase I/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination With Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors
Description: The purpose of this study is to assess the safety and tolerability, characterize the dose-limiting toxicities, and identify the maximum tolerated dose of BMS-986016 alone and in combination with Nivolumab in subjects with select advanced (metastatic and/or unresectable) solid tumors and to provide preliminary information on the clinical benefits of the combination.
To refer a patient for a Phase I study, please complete this form.
To see our complete list of open Phase I studies, click here.
To see all open Providence studies in all cancer types, click here.